# OnCo record paper-portec-3-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-portec-3-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-portec-3-lancet-oncol-2018" ;
  schema:name "PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer"@en ;
  schema:description "Adding cisplatin during pelvic radiotherapy and four cycles of carboplatin-paclitaxel afterwards improved failure-free survival in high-risk endometrial cancer, most clearly in stage III and serous cancers, at the cost of more toxicity."@en ;
  schema:url <https://onco.cc/key-papers/paper-portec-3-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30079-2>, <https://pubmed.ncbi.nlm.nih.gov/29449189/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30079-2> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "de Boer SM, Powell ME, Mileshkin L, et al." ;
  onco:cancers <https://onco.cc/cancers/endometrial-p53-abnormal/> ;
  onco:trials <https://onco.cc/trials/portec-3/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .